ZIM
CPRX icon

Zacks Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Zacks Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-155,424
Closed -$303K – 685
2013
Q4 		$303K Buy
+155,424
New +$314K 0.01% 538

Other funds holding CPRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tanaka Capital Management New York $59.9M AUM

Zacks Investment Management's CPRX Position: Q1 2014 in Review

Zacks Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2014, closing a stake of 155,424 shares — an estimated $303K sold.

Zacks Investment Management first reported a position in CPRX in Q4 2013 and held it in 1 quarter. The position peaked at $303K in Q4 2013. 38 funds tracked by Wall St. Rank hold CPRX as of Q1 2014.

  • Zacks Investment Management reported no remaining Catalyst Pharmaceutical position as of Q1 2014 after selling out during the quarter.
  • Zacks Investment Management sold 155,424 Catalyst Pharmaceutical shares in Q1 2014, an estimated $303K.
  • Zacks Investment Management first reported a position in Catalyst Pharmaceutical in Q4 2013 and held it in 1 quarter.
  • Zacks Investment Management's Catalyst Pharmaceutical position peaked at $303K in Q4 2013.
  • 38 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2014.

Based on Zacks Investment Management's 13F filing for Q1 2014, filed 13 May 2014.